Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial

Breast Cancer Research and Treatment

Volumn 126, Issue 1, 2011, Pages 221-226

  Phillips, Kelly Anne ^a   Aldridge, Julie ^b   Ribi, Karin ^c   Sun, Zhuoxin ^b   Thompson, Alastair ^d   Harvey, Vernon ^e,f   Thürlimann, Beat ^g,h   Cardoso, Fatima ⁱ   Pagani, Olivia ^h,j   Coates, Alan S ^k,l   Goldhirsch, Aron ^j,m   Price, Karen N ⁿ   Gelber, Richard D ⁿ   Bernhard, Jürg ^c,o  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c IBCSG Coordinating Center   (Switzerland)

^d UNIVERSITY OF DUNDEE   (United Kingdom)

^e AUCKLAND CITY HOSPITAL   (New Zealand)

^f Australian New Zealand Breast Cancer Trials Group   (Australia)

^g Breast Center   (Switzerland)

^h SWISS GROUP FOR CLINICAL CANCER RESEARCH SAKK   (Switzerland)

ⁱ JULES BORDET INSTITUTE   (Belgium)

^j ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^k International Breast Cancer Study Group   (Switzerland)

^l UNIVERSITY OF SYDNEY   (Australia)

^m EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

ⁿ FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^o UNIVERSITY OF BERN   (Switzerland)

more..

Author keywords

Aromatase inhibitor; Breast cancer; Cognitive function; Letrozole; Quality of life; Tamoxifen

Indexed keywords

LETROZOLE; TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CLINICAL ASSESSMENT; COGNITION; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; FEMALE; FUNCTIONAL ASSESSMENT; HORMONAL THERAPY; HUMAN; LEARNING; MAJOR CLINICAL STUDY; MEMORY; POSTMENOPAUSE; PRIORITY JOURNAL; SCORING SYSTEM; TASK PERFORMANCE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COGNITION; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INTERNATIONAL AGENCIES; LONGITUDINAL STUDIES; MENOPAUSE; NITRILES; PROGNOSIS; SURVIVAL RATE; TAMOXIFEN; TRIAZOLES;

EID: 79151479469     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-1235-y     Document Type: Article

References (17)

1. KS McCarty Jr JS Silva EB Cox, et al. 1983 Relationship of age and menopausal status to estrogen receptor content in primary carcinoma of the breast Ann Surg 197 123 127 10.1097/00000658-198302000-00001 6824366
2. CM Schilder C Seynaeve WB Beex, et al. 2010 Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial J Clin Oncol 28 1294 1300 1:CAS:528:DC%2BC3cXksFSqtbo%3D 10.1200/JCO.2008.21.3553 20142601
3. B Collins J Mackenzie A Stewart, et al. 2009 Cognitive effects of hormonal therapy in early stage breast cancer patients: a prospective study Psychooncology 18 811 821 10.1002/pon.1453 19085975 (Pubitemid 351279862)
4. CM Bender SM Sereika SL Berga, et al. 2006 Cognitive impairment associated with adjuvant therapy in breast cancer Psychooncology 15 422 430 10.1002/pon.964 16097037 (Pubitemid 43826855)
5. V Jenkins V Shilling L Fallowfield, et al. 2004 Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study Psychooncology 13 61 66 10.1002/pon.709 14745746 (Pubitemid 38139358)
6. KA Phillips K Ribi Z Sun, et al. 2010 Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomised trial Breast 19 388 395 10.1016/j.breast.2010.03.025 20385495
7. V Jenkins LM Ambroisine L Atkins, et al. 2008 Effects of anastrozole on cognitive performance in postmenopausal women: a randomized, double-blind chemoprevention trial (IBIS II) Lancet Oncol 9 953 961 1:CAS:528: DC%2BD1cXhtFOmurvP 10.1016/S1470-2045(08)70207-9 18768369
8. BIG 1-98 Collaborative Group 2005 A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer N Engl J Med 353 2747 2757 10.1056/NEJMoa052258 (Pubitemid 43016814)
9. BIG 1-98 Collaborative Group 2009 Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer N Engl J Med 361 766 776 10.1056/NEJMoa0810818
10. J Vardy K Wong QL Yi, et al. 2006 Assessing cognitive function in cancer patients Support Care Cancer 14 1111 1118 10.1007/s00520-006-0037-6 16538498 (Pubitemid 44898793)
11. MG Falleti P Maruff A Collie, et al. 2003 Qualitative similarities in cognitive impairment associated with 24 h of sustained wakefulness and a blood alcohol concentration of 0.05% J Sleep Res 12 265 274 10.1111/j.1365-2869.2003. 00363.x 14633237 (Pubitemid 38010432)
12. PJ Snyder J Werth B Giordani, et al. 2005 A method for determining the magnitude of change across difference cognitive functions in clinical trials: the effects of acute administration of two different doses of alprazolam Hum Psychopharmacol 20 263 273 1:CAS:528:DC%2BD2MXmt1Clsro%3D 10.1002/hup.692 15912482 (Pubitemid 40873464)
13. A Collie D Darby P Maruff 2001 Computerized cognitive assessment of athletes with sports related head injury Br J Sports Med 35 279 302 10.1136/bjsm.35.5.297 (Pubitemid 32929812)
14. P Maruff E Thomas L Cysique, et al. 2009 Validity of the CogState brief battery: relationship to standardized tests and sensitivity to cognitive impairment in mild traumatic brain injury, schizophrenia, and AIDS dementia complex Arch Clin Neuropsychol 24 165 178 10.1093/arclin/acp010 19395350
15. BY Silber RJ Croft K Papafotiou C Stough 2006 The acute effects of d-amphetamine and methamphetamine on attention and psychomotor performance Psychopharmacology 187 154 169 1:CAS:528:DC%2BD28Xms1Gqur8%3D 10.1007/s00213-006-0410-7 16761129 (Pubitemid 44015610)
16. MT Fillmore TH Kelly CA Martin 2005 Effects of d-amphetamine in human models of information processing and inhibitory control Drug Alcohol Depend 77 151 159 1:CAS:528:DC%2BD2MXmsVCmtA%3D%3D 10.1016/j.drugalcdep.2004.07.013 15664716 (Pubitemid 40128193)
17. Buchanan RW, Keefe RS, Umbricht D et al The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later? Schizophr Bull (in press)